Discovery of reversible selective MAO-B inhibitors with anti-AChE activity derived from 4-oxo-N, 4-diphenyl butanamides - Supplementary Material

<strong>Table S1.</strong> Docking results of 4-oxo-N, 4-diphenyl butanamides against AChE, and MAOs. <strong>Table S2.</strong> Calculated physiochemical descriptors of 4-oxo-N, 4-diphenyl butanamides using QikProp <strong>Table S3 </strong>Compound purity by HPLC (method): <strong>Figure S1.</strong> HPLC Chromatogram (tR, 3.007 min) of compound <strong>6h</strong> at 250 nm. <strong>Table S4</strong> Permeability of nine commercial drugs used for validation of PAMPA-BBB assay <strong>Figure S2. </strong>Linear correlation chart of experimental and literature reported permeability of commercial drugs for PAMPA-BBB assay. <strong>Table S5.</strong> Permeability of 4-oxo-N, 4-diphenyl butanamides determined by BBB-PAMPA assay <br> <strong>Table S6.</strong> Cell viability and neuroprotection of synthesized compounds on SH-SY5Y cell line ^{<strong>1</strong>}<strong>H &amp; </strong>^{<strong>13</strong>}<strong>C NMR spectra of Synthesised compounds:</strong>